ASGR1

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Retrieved on: 
星期三, 六月 12, 2024

SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS (Surrozen Wnt signal Enhancer Engineered for Tissue Specificity) bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications (Click: HERE).

Key Points: 
  • These ASGR-targeted SWEETS molecules represent a unique targeted protein degradation (TPD) platform, that functions via multiple mechanisms, and expands the potential opportunities to treat liver diseases through cell or tissue-specific regenerative therapeutics with enhanced Wnt signal activation.
  • This review article provided a comprehensive summary of work done by both Surrozen scientists and other researchers in the field on the invention of various Wnt activating platforms.
  • This review highlights the exciting progress made in this emerging field and the potential of Wnt agonists in the treatment of numerous tissue degenerative diseases.
  • *TPD – Total protein degradation technologies focus on the complex networks of biochemical processes in protein homeostasis and includes removal of damaged proteins and targeted degradation of intracellular, extracellular, and cell-surface proteins with unwanted functions

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Retrieved on: 
星期一, 四月 1, 2024

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today provided an update on the Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis.   The Phase 1a study was completed in February 2024. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.   The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.

Key Points: 
  • SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.
  • The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.
  • The randomized, placebo-controlled Phase 1a trial enrolled a total of 48 subjects, including 40 healthy volunteers and 8 patients with cirrhosis and a history of liver disease.
  • Cirrhotic patients also showed evidence of liver function effects after treatment with SZN-043 as measured by HepQuant which is a test that measures cholate clearance, a liver specific function that quantifies liver function.

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 12, 2022

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Initiated Phase 1-enabling toxicology study for SBT8230 in the first quarter of 2022 and on track to complete Phase 1 regulatory submission in the fourth quarter of 2022.
  • Silverback continues to advance discovery programs, with an update anticipated in the fourth quarter of 2022.
  • For the first quarter ended March 31, 2022, Silverback reported a net loss of $24.6 million, compared to a net loss of $18.9 million for the comparable period in 2021.

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
星期四, 三月 31, 2022

We continue to advance SBT8230 and are on track to complete a Phase 1 regulatory submission in the fourth quarter of 2022.

Key Points: 
  • We continue to advance SBT8230 and are on track to complete a Phase 1 regulatory submission in the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter ended December 31, 2021 were $15.9 million, compared to $8.8 million for the same period in 2020.
  • Silverback also incurred additional personnel-related expenses in 2021 as compared to 2020 as operations grew in support of program advances.
  • General and administrative expenses for the fourth quarter ended December 31, 2021 were $7.6 million, compared to $4.3 million for the same period in 2020.

Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021

Retrieved on: 
星期五, 十一月 12, 2021

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021.
  • Our preclinical studies demonstrate that SBT8230 is efficiently delivered to the liver.
  • This results in myeloid cell activation in liver, but not in blood.
  • The poster is now available on the AASLD website and on the Silverback website here .